Clinical Trial Update: Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating toripalimab alone or in combination with tifcemalimab as consolidation therapy for limited-stage small cell lung cancer is currently re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Tifcemalimab (tifcemalimab)
• Toripalimab (Toripalimab)

Snippet

Sponsor: Shanghai Junshi Bioscience Co., Ltd. | Conditions: Limited-stage Small Cell Lung Cancer (LS-SCLC) | Phase 3 | Status: RECRUITING